Project LiBRha aims to improve pediatric STS diagnosis and treatment through comprehensive molecular testing and liquid biopsy integration. The initiative involves 18 centers and partnerships with the ...

Actuate Therapeutics, Inc. has announced the completion of the Phase 1 study evaluating its drug elraglusib in pediatric patients with refractory malignancies, specifically Ewing Sarcoma (EWS). The ...

Kaposi's sarcoma (KS) is a low-grade vascular neoplasm mediated by the human herpesvirus-8. Only 1 clinical subtype, the endemic/African subtype, commonly affects the pediatric population. Although ...

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) ...

CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

RMS of the chest wall is rare, comprising only 2% of RMS cases, with a 5-year overall survival rate of 61%. The consensus document was developed by global pediatric sarcoma groups, covering staging, ...

Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and Adolescents Ongoing Enrollment in Phase 1/2 Trial of Elraglusib in ...

CHICAGO – An artificial intelligence (AI)-based model accurately classified pediatric sarcomas using digital pathology images alone, according to results presented at the American Association for ...

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer Safety and Tolerability of ...

Phase I Trial of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Doxorubicin and Cyclophosphamide in Children With Relapsed Solid Tumors: A Children's Oncology Group Study Thromboembolism is ...